drugset / Trial / NCT03701698
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
Phase 2
Terminated
1 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
Timeline
- Start
- 2018-11-01
- Primary completion
- 2024-09-20
- Completion
- 2024-09-20
Outcome
Outcome not reported
Stopped (Enrollment): “Participants recruitment failure”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Background | Methylprednisolone | Other / unclassified | 2 mg/kg | Intravenous |